OSAKA, Japan--(BUSINESS WIRE)--In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation ...
New York, USA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | ...
The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...
The informational nature of oligonucleotide drugs 1 (i.e., drugs designed on the basis on sequence information) promised to lend itself well to the postgenomic era of medicine. Researchers were drawn ...
Oligonucleotide therapeutics make up a small but rapidly growing segment of the overall global drug pipeline, with 245 programs currently in development today. While only one approved oligo ...
The 4-year deal is a big one for GSK, which has three oligo drug candidates in Phase 2 studies for hepatitis B. It’s even bigger for Wave. And it’s just one of several recent pacts highlighting the ...
Please provide your email address to receive an email when new articles are posted on . Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential ...
The global oligonucleotide API market is poised to grow from USD 2.81 billion in 2024 to USD 4.84 billion by 2034, expanding at a CAGR of 5.60%. The increasing need for innovative drug classes and ...
Zacks Small Cap Research on MSN
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration
PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO ...
A new platform for making oligonucleotides offers chemists a way to plug in five types of nucleoside connections, so they can tailor properties of oligonucleotide therapeutics. These short DNA or RNA ...
MyChesCo on MSN
Rockland Immunochemicals Advances Oligonucleotide Therapeutics with Novel Bioanalytical Technology
LIMERICK, PA — Rockland Immunochemicals, Inc., in collaboration with researchers from the Nucleic Acid Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback